The extensive literature surrounding the biology of CXCR4 and its binding partner CXCL12 in health and disease, and the ready availability of targeted therapeutic agents make CXCR4 a particularly attractive candidate for further genetic replication and functional investigation of its pathogenic role and therapeutic potential in JIA and other autoimmune diseases affecting children. Here, CXCR4 is linked to autoimmune disease.